Singular Genomics Systems (NASDAQ:OMIC) Trading Up 0.7% – Should You Buy?

Singular Genomics Systems, Inc. (NASDAQ:OMICGet Free Report)’s stock price was up 0.7% during mid-day trading on Tuesday . The company traded as high as $19.90 and last traded at $20.01. Approximately 3,306 shares were traded during trading, a decline of 67% from the average daily volume of 10,162 shares. The stock had previously closed at $19.86.

Singular Genomics Systems Stock Performance

The stock’s 50-day moving average is $19.98 and its 200-day moving average is $15.37. The company has a current ratio of 7.37, a quick ratio of 6.67 and a debt-to-equity ratio of 0.04. The stock has a market cap of $50.75 million, a price-to-earnings ratio of -0.57 and a beta of 1.83.

Singular Genomics Systems (NASDAQ:OMICGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.05) by $1.33. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative return on equity of 57.87%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.74 million.

Institutional Investors Weigh In On Singular Genomics Systems

An institutional investor recently raised its position in Singular Genomics Systems stock. Geode Capital Management LLC boosted its stake in Singular Genomics Systems, Inc. (NASDAQ:OMICFree Report) by 7.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,962 shares of the company’s stock after acquiring an additional 1,193 shares during the quarter. Geode Capital Management LLC owned about 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent reporting period. 65.80% of the stock is currently owned by institutional investors.

Singular Genomics Systems Company Profile

(Get Free Report)

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.

Featured Articles

Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.